
ME Therapeutics Licenses CD22 Nanobody to Advance In Vivo CAR Therapy Program
The agreement strengthens ME Therapeutics’ next-generation in vivo CAR cell therapy platform, expanding its pipeline targeting B-cell malignancies through innovative nanobody-based technologies. ME Therapeutics Holdings Inc. (“ME Therapeutics” or the “Company”) (CSE: METX) (FSE: Q9T), a publicly listed biotechnology company…











